Beamtree Holdings Ltd · ASX:BMT
Beamtree — Investor Presentation (August 2022)
28 slides from Beamtree's investor presentation, Aug 24, 2022
Slide 1: FY22 Annual Results
FY22 Annual Results 24th August, 2022
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer The material in this presentation is general background information about Beamtree Holdings Limited (ASX:BMT) and is current at the date of the presentation, 24 August 2022. This presentation may contain statements that are, or may be deemed to be, forward looking sta
Slide 3: FY22 Highlights
FY22 Highlights Copyright © Beamtree Holdings Limited – All Rights Reserved 2
Slide 4: FY22 Key Strategic Highlights
FY22 Key Strategic Highlights Two important acquisitions completed in FY22, doubling the size of Beamtree 1. Acquisition of Potential(x) in Sept 2021, one of Australia’s largest health data analytics company 2. Acquisition of Ainsoff to drive AI product innovation and add to our clinical decision su
Slide 5: FY22 Financial Highlights
FY22 Financial Highlights 172% 97% 43% PCP* PCP PCP** Annual recurring Reported International Cash Revenue Revenue Revenue $18.2M $16.5M $4.1M $6.3M Strong cash position with 2H FY22 operating cash flow broadly neutral Excludes $2m large one-off receivable expected in 1H FY23 * Prior Corresponding P
Slide 6: FY23 Outlook
FY23 Outlook Revenue • July 2022 trading conditions remain positive with like for like sales up 17% on the prior year. • Total reported revenue growth target of ~35% in FY23. • Sales pipeline continues to build particularly the International sales pipeline which is significantly larger versus prior
Slide 7: Long Term Outlook
Long Term Outlook ARR* $60M Revenue 35% CAGR Contribution % ~35-40% ARR* $18M ~15-20% Revenue Contribution % ~15-20% ~30% <5% ~25% ~30% ~45% Analytics & Knowledge Networks Coding Assistance and Data Quality 2022 Clinical Decision Support (CDS) Diagnostic Technology 2026 * Annual recurring revenue “A
Slide 8: Beamtree Strategy
Beamtree Strategy Copyright © Beamtree Holdings Limited – All Rights Reserved 7
Slide 9: Creating a better future for health
Creating a better future for health We provide AI decision support and data insights solutions with the aim of turning data into insights and action through automation. We believe it starts with better data and ends in better care – and that ‘better has no limit’
Slide 10: About Us
About Us 25+ years of experience Australian company with Supporting healthcare Cutting-edge use of AI Australian IP globally and machine learning Four Key Areas: Diagnostic Technology Clinical Decision Support Coding Assistance & Data Analytics & Knowledge Quality Networks Copyright © Beamtree Holdi
Slide 11: Beamtree's History
Beamtree’s History Pacific Knowledge Systems ° Est. 1999 - Listed 2019 ippleDown RippleDown Ainsoff od Est. 2018 - Acq. 2021 Ainsoff Aiscribe Ailert slo oo 945, < Yg s” %, “@ Fe. x “9, S co § 3 & 2 ro) % z Beamtree S inf 9, & 2. é ©, = & g %5, : x % %, Ss %, C2 Lor, noo ye? e Pavilion Health Est. 20
Slide 12: Supporting Healthcare Providers Globally
Supporting Healthcare Providers Globally We support 175+ clients who operate across 6 25 1100+ Continents Countries Locations
Slide 13: How we create value: the Learning Health System
How we create value: the Learning Health System Driving continuous improvement by better access to healthcare information – towards safety, quality and efficiency. Return knowledge to Collect health the rules engine information Support clinicians Encode in coders and administrators standard formats
Slide 14: Better Has No Limit: The Problems We Help Solve
Better Has No Limit: The Problems We Help Solve Tackle unwarranted Offer revenue Promote transparency Drive automation variation assurance Address equity Bridge knowledge gaps Increase efficiency, Improve quality of access and resource reducing mistakes of data allocation Copyright © Beamtree Holdin
Slide 15: Growth Strategy driven by four product segments
Growth Strategy driven by four product segments Diagnostic Technology Coding Assistance and Data Quality Enabling the effective delivery of diagnostic Digitising and automating workflows with data, services, while maximising expertise as they classification, coding & technical expertise to underpin
Slide 16: Beamtree's Key Areas, Key Products and What They Do
Beamtree’s Key Areas, Key Products and What They Do Product/ Solutions Application Problem Solved ROI Pricing/Scale Removes duplication Leverages clinical resources Recurring Clinical rules to automate for experts in by using less License + volume expert decision making in Diagnostics providing diag
Slide 17: Highlights of FY22
PICQ® & RISQ™ User Group with 200+ attendees Highlights of FY22 UK contracts for decision support in NHS hospitals Extension of First contract to trial Production of new BI Platform for hospital-acquired RippleDown® Ainsoff Index™ in complications global distribution Hong Kong partnership First cont
Slide 18: Recent Contract Wins
Recent Contract Wins Product/ Solutions Recent Contract Wins Going Forward • Largest ever RippleDown contract (US$7M 5 year) with a large global pathology group • ~30% of FY22 revenue Diagnostic • Focus on international • New contract agreement with Australian Pathology operators in Q4 FY22 Technolo
Slide 19: FY22 Acquisition - Update
FY22 Acquisition - Update Potential(x) Ainsoff • Acquired 30 Sept 2021 • Acquired August 2021 • Australia’s largest health care data analytics • $1.5m additional capital invested in Ainsoff company since acquisition • Performing in line with expectations and • ~$2m investment expected in FY23 histor
Slide 20: FY22 Financial Results
FY22 Financial Results Copyright © Beamtree Holdings Limited – All Rights Reserved 19
Slide 21: FY22 Summary Profit and Loss
FY22 Summary Profit and Loss Highlights FY22 FY21 Change P&L ($M) Actual Actual FY22-21 Group Revenue Revenue Annual recurring revenue (ARR) 16.5 18.2 8.4 6.7 97% 172% 97% Expenses – staff (14.2) (4.7) 203% Expenses – non staff (6.3) (2.8) 125% Total operating expenses (20.6) (7.5) 174% ARR Operatin
Slide 22: Annual Recurring Revenue Growth
Annual Recurring Revenue* (ARR) Growth ($’M) +172% PCP • +172% growth in Annual (+30% organic PCP) Recurring Revenue (ARR) has been driven by $9.5m (142%) 2.0 18.2 contribution from Potential(x) and $2.0m 9.5 organic growth (30%) • Organic growth in ARR is +30% in FY22 vs. FY21, largely +15% driven
Slide 23: Reported Revenue Growth
Reported Revenue Growth ($’M) +97% PCP (+14% organic PCP*) Comments 16.5 • +97% PCP growth in Reported Revenue in FY22 has been driven by $7.7m contribution from Potential (x) and 7.7 $0.5m organic growth. +103% PCP (+15% organic PCP) • FY22 organic growth of 14% PCP excl. one-off Saudi advisory ser
Slide 24: Operating Expenses & Investments
Operating Expenses & Investments Operating expense increase FY20 – FY22 ($M) Organic Operating expense increase ($M) 20.6 FY21 7.5 6.8 Ainsoff 1.6 $13.5m 174% International Sales 1.0 Sales & Commercial $6.3m 0.5 $4.4m 13.8 141% Product & technology 2.2 7.5 3.1 Back office support 1.0 FY20 FY21 FY22
Slide 25: Operating Profit and Reported EBITDA
Operating Profit and Reported EBITDA Operating Profit ($M) Reported EBITDA ($M) 1.0 0.8 1.2 0.9 FY20 FY21 FY22 FY22 FY20 FY21 FY22 FY22 (4.0) (2.3) • Operating loss driven by investment of more than FY20 FY21 FY22 $5m in our capabilities, both product and people. Operating Profit 1.2 0.9 (4.0) Forei
Slide 26: Balance Sheet
Balance Sheet FY22 FY21 CONSOLIDATED GROUP ($M) Actual Actual Comments Current assets Cash & cash equivalents 6.4 14.1 Trade & other receivables 6.9 2.1 $6.4m cash , Contracts 0.1 1.1 Total current assets 13.3 17.4 2H cash burn broadly neutral Non current assets Property plant & equipment 0.4 0.6 Ri
Slide 27: Cashflow
Cashflow Comments FY22 1H FY22 FY21 2H FY22 CONSOLIDATED GROUP ($M) Actual Actual Actual CASHFLOWS FROM OPERATING ACTIVITIES Receipts from customers 17.5 6.6 7.4 Operating net cash Payments to suppliers and employees (20.6) (8.9) (7.7) broadly neutral Other receipts/(paid) 0.8 0.0 0.6 Net cash provi
Slide 28: Thank you
Thank you Copyright © Beamtree Holdings Limited – All Rights Reserved 27
Beamtree Holdings — Investor Presentation (August 2022) on 6ix